Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 26 analyst ratings
Hold
Strong Buy 19%
Buy 8%
Hold 58%
Sell 15%
Strong Sell 0%

Bulls say

Moderna's stock outlook remains positive due to its expanding portfolio, which includes 40 mRNA candidates across various therapeutic areas like oncology and infectious diseases, indicating strong growth potential. The company's valuation of key developmental candidates, such as mRNA-4157, has risen to $2.79 billion, showcasing confidence in its future revenue streams from innovative therapies. Additionally, Moderna's commitment to preventive vaccines and alignment with ESG principles supports a sustainable growth model, further enhancing its overall financial stability and resilience in the biotech sector.

Bears say

Moderna has reported a significant decline in COVID vaccine sales, with revenues dropping from $18 billion in 2022 to $6.7 billion in 2023, prompting a downward revision of guidance for 2024 due to anticipated market headwinds. The company's valuation of its key products, including Spikevax, has also decreased sharply, reflecting reduced expectations for long-term COVID-related sales, which are now projected to fall further as the pandemic transitions to an endemic phase. Overall, the firm's financial outlook is clouded by uncertainties regarding vaccination rates and limited contributions from other vaccine candidates, leading to expectations of flat or declining top-line revenue through 2025.

Moderna (MRNA) has been analyzed by 26 analysts, with a consensus rating of Hold. 19% of analysts recommend a Strong Buy, 8% recommend Buy, 58% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 26 analysts, Moderna (MRNA) has a Hold consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.